{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:10:52Z","timestamp":1777893052608,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["219878"],"award-info":[{"award-number":["219878"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cllc.2025.12.007","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:25:03Z","timestamp":1767831903000},"page":"224-234.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced\/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England"],"prefix":"10.1016","volume":"27","author":[{"given":"Fabio","family":"Gomes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niall","family":"Gilding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Christoforou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Rule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amine","family":"Aziez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Januszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Minchom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2025.12.007_bib0001","unstructured":"Cancer Research UK. Lung cancer statistics. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/lung-cancer, 2023. (Accessed: 20 February, 2024)."},{"key":"10.1016\/j.cllc.2025.12.007_bib0002","unstructured":"Cancer Research UK. Types of lung cancer. https:\/\/www.cancerresearchuk.org\/about-cancer\/lung-cancer\/stages-types-grades\/types#:~:text=Around%2080%20to%2085%20out,carcinoma%20and%20large%20cell%20carcinoma, 2022. (Accessed: 21 February, 2024)."},{"key":"10.1016\/j.cllc.2025.12.007_bib0003","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4132\/jptm.2019.04.24","article-title":"PD-L1 testing in non-small cell lung cancer: past, present, and future","volume":"53","author":"Kim","year":"2019","journal-title":"J Pathol Transl Med"},{"key":"10.1016\/j.cllc.2025.12.007_bib0004","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2025.12.007_bib0005","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer. https:\/\/www.nice.org.uk\/guidance\/ta683\/resources\/pembrolizumab-with-pemetrexed-and-platinum-chemotherapy-for-untreated-metastatic-nonsquamous-nonsmallcell-lung-cancer-pdf-82609378374085, 2021. (Accessed: July 23, 2024)."},{"key":"10.1016\/j.cllc.2025.12.007_bib0006","unstructured":"National Institute for Health and Care Excellence. Pemetrexed maintenance treatment for nonsquamous non-small-cell lung cancer after pemetrexed and cisplatin. https:\/\/www.nice.org.uk\/guidance\/ta402\/resources\/pemetrexed-maintenance-treatment-for-nonsquamous-nonsmallcell-lung-cancer-after-pemetrexed-and-cisplatin-pdf-82604539400389, 2016. (Accessed: July 23, 2024)."},{"key":"10.1016\/j.cllc.2025.12.007_bib0007","unstructured":"NHS England. NHS England interim treatment options during the COVID-19 pandemic. https:\/\/www.theacp.org.uk\/userfiles\/file\/resources\/covid_19_resources\/nhs-england-interim-treatment-options-during-the-covid19-pandemic-pdf-8715724381-6-jan-2021.pdf, 2021. (Accessed: March 12, 2024)."},{"key":"10.1016\/j.cllc.2025.12.007_bib0008","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.12.007_bib0009","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.12.007_bib0010","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.12.007_bib0011","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2025.12.007_bib0012","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.12.007_bib0013","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2217\/imt-2022-0166","article-title":"Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA","volume":"15","author":"Aggarwal","year":"2023","journal-title":"Immunotherapy"},{"key":"10.1016\/j.cllc.2025.12.007_bib0014","doi-asserted-by":"crossref","first-page":"9222","DOI":"10.1038\/s41598-021-88453-8","article-title":"Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices","volume":"11","author":"Velcheti","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2025.12.007_bib0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2217\/imt-2023-0313","article-title":"Outcomes for pembrolizumab stratified by pemetrexed maintenance post pembrolizumab-platinum-pemetrexed induction in metastatic non-small-cell lung cancer","volume":"16","author":"Goldschmidt","year":"2024","journal-title":"Immunotherapy"},{"key":"10.1016\/j.cllc.2025.12.007_bib0016","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00884-2018","article-title":"Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study","volume":"52","author":"Visser","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cllc.2025.12.007_bib0017","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3390\/curroncol31030119","article-title":"Real-world evidence of the impact of the COVID-19 pandemic on lung cancer survival: canadian perspective","volume":"31","author":"Agulnik","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cllc.2025.12.007_bib0018","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.3390\/curroncol28060360","article-title":"The impact of COVID-19 on the diagnosis and treatment of lung cancer at a Canadian academic center: a retrospective chart review","volume":"28","author":"Kasymjanova","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cllc.2025.12.007_bib0019","doi-asserted-by":"crossref","first-page":"8677","DOI":"10.3390\/curroncol29110684","article-title":"The impact of COVID-19 on the diagnosis and treatment of lung cancer over a 2-year period at a Canadian academic center","volume":"29","author":"Kasymjanova","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cllc.2025.12.007_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000344","article-title":"Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?","volume":"3","author":"Pinto","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.cllc.2025.12.007_bib0021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jnci\/94.3.173","article-title":"Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial","volume":"94","author":"Langer","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2025.12.007_bib0022","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/cncr.21495","article-title":"Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326)","volume":"104","author":"Belani","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2025.12.007_bib0023","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jgo.2018.05.006","article-title":"Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622)","volume":"9","author":"Feliciano","year":"2018","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.cllc.2025.12.007_bib0024","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/s12885-022-09674-2","article-title":"Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study","volume":"22","author":"Gu","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2025.12.007_bib0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/jcpt.13534","article-title":"The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab\/pemetrexed alone for stage IIIB\/IV nonsquamous non-small cell lung cancer: a meta-analysis of randomized controlled trials","volume":"47","author":"Liu","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.cllc.2025.12.007_bib0026","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jtho.2020.04.021","article-title":"Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC","volume":"15","author":"Dumoulin","year":"2020","journal-title":"J Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425003353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425003353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:46:34Z","timestamp":1777617994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425003353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1525730425003353"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.12.007","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced\/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}